Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on December 18, 2017, 10:31:01 am
-
The checkpoint inhibitor Opdivo (nivolumab), which helps the immune system fight cancer, led to tumor shrinkage or stable disease in more than half of treated patients with liver cancer, according to results from the Checkmate 040 trial presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, held last week in Washington, DC.
These extended follow-up results were the basis for the Food and Drug Administration’s September approval of Opdivo for the treatment of people with liver cancer who previously used the kinase inhibitor Nexavar (sorafenib), the only approved first-line therapy, according to Bristol-Myers Squibb.
Read more...
https://www.hepmag.com/article/opdivo-immunotherapy-liver-cancer
-
Good news